Skip to main content
. 2023 May 22;10:765–781. doi: 10.2147/JHC.S407536

Figure 10.

Figure 10

(A) Overexpression of GRB2 predicted a better immunotherapy response (p < 0.01). (B) Overexpression of GRB2 predicted resistance to Sorafenib. (C) Low-expression GRB2 had a better TACE response.